172
Views
4
CrossRef citations to date
0
Altmetric
Editorial

Evaluating the ‘real’ cost-effectiveness of health technology: reconciling the public interest with patients’ interests

&
Pages S1-S6 | Accepted 11 Jan 2007, Published online: 07 Feb 2007

References

  • Hjelmgren J, Berggren F, Andersson F. Health economic guidelines – similarities, differences and some implications. Value Health 2001;4:225–50
  • Raftery JP. Review of NICE’s recommendations, 1999–2005. BMJ 2006;332:1266–8
  • Dillon A. Letter to manufacturers regarding transfer to STA process. NICE, 29 November 2005 Available at: www.nice.org.uk/download.aspx?o=281942> (last accessed: 25th July 2006)
  • McEwan P, Poole CD, Tetlow T, et al. Evaluation of the cost effectiveness of insulin glargine versus NPH insulin for the treatment of type 1 diabetes in the UK. Curr Med Res Opin 2007;23(Suppl 1):S17–19
  • McEwan P, Poole CD, Tetlow T, et al. Evaluation of the cost effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK. Curr Med Res Opin 2007;23(Suppl 1):S21–31
  • Rothwell PM. External validity of randomised controlled trials: ‘To whom do the results of this trial apply?’ Lancet 2005;365:82–93
  • Currie CJ, Poole CD, Tetlow T, et al. The outcome of care in people with type 1 and type 2 diabetes following switching to treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis. Curr Med Res Opin 2007;23(Suppl 1):S33–39
  • Poole CD, Tetlow T, McEwan P, et al. The prescription cost of managing people with type 1 and type 2 diabetes following initiation of treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis. Curr Med Res Opin 2007;23(Suppl 1):S41–48
  • Pieber TR, Treichel HC, Robertson LI, et al. Detemir plus insulin aspart is associated with less risk of major as well as nocturnal hypoglycaemia than insulin glargine plus insulin aspart at comparable levels of glycaemic control in type 1 diabetes. Diabetologia 2005;48(Suppl 1):A92–2
  • Warren E, Weatherly-Jones E, Chilcott J, et al. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technol Assess 2004;8(45):iii, 1–57
  • Currie CJ, Morgan CLl, Poole CD, et al. Multivariate models of health related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006;22:1523–34
  • Leese GP, Wang J, Broomhall J, et al. Frequency of severe hypoglycaemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003;26:1176–80
  • The DCCT Study Group. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. Am J Med 1991;90:450–9
  • NICE. Guide to the single technology appraisal (STA) process (Interim process). 11 November 2005. Available from: www.nice.org.uk/page.aspx?o=278616 [Last accessed 25 April 2006]
  • NICE. The guidelines manual – Chapter 7: Reviewing and grading the evidence. London: NICE, 2006
  • Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ 2001;323:334–6
  • NICE. The guidelines manual – Chapter 8: Incorporating health economics in guidelines and assessing resource impact. London: NICE, 2006
  • Centre for Reviews and Dissemination, University of York. Available from: www.york.ac.uk/inst/crd [Last accessed: 20 July 2006]
  • Drummond M, Davies L. Economic analysis alongside clinical trials: revisiting the methodological issues. Int J Technol Assess Health Care 1991;7:561–73
  • O’Brien B. Economic evaluation of pharmaceuticals: Frankenstein’s monster or vampire of trials. Medical Care 1996;34 (12 Suppl):DS99–108
  • Braunholtz DA, Edwards SJL, Lilford RJ. Are randomized clinical trials good for us (in the short term)? Evidence for a ‘trial effect.’ J Clin Epidemiol 2001;54:217–24
  • National Institute for Clinical Excellence. Appraisal Consultation Document: The clinical effectiveness and cost effectiveness of long acting insulin analogues for diabetes. Available at: www.nice.org.uk/page.aspx?o=35497 [Last accessed: 25 October 2005]
  • Misbin RI. Medical Review of detemir (NDA 021–536). Centre for Drug Evaluation & Research, US Food and Drug Administration. 9th June 2005. <http://www.fda.gov/cder/foi/nda/2005/021�536_levemir_medr.pdf> (last accessed: 20th June 2006)
  • Insulin detemir (rys) cartridge 3 mL (Penfill ), prefilled device 3 mL (FlexPen), 100 U/mL, Levemir, July 2005. Department of Health and Government, Australia. Available at: www.health.gov.au/internet/wcms/publishing.nsf/Content/pbac-psdinsulind [Last accessed 4 May, 2006]
  • Russmann A, Schreiber S. Treatment with insulin glargine of patients with type 1 diabetes in clinical practice: metabolic control over 30 months. Diabetologia 2004;47\(Suppl. 1): [Abstract 842]
  • Schreiber, S, Russmann, A. Treatment with insulin glargine of patients with type 2 diabetes in clinical practice: metabolic control over 30 months. Diabetologia 2004;47(Suppl 1): A271 [Abstract 748]
  • Winocour PH. Effective diabetes care: a need for realistic targets. BMJ 2002;324:1577–80
  • Fanelli CG, Porcellati F, Pampanelli S, Bolli GB. Insulin therapy and hypoglycemia: the size of the problem. Diabetes Metab Res Rev 2004;20(Suppl 2):S32–42
  • Insulin Glargine, injection, 100 units per mL, 10 mL vials and 3 mL x 5 cartridges, Lantus®, July 2005. Department of Health and Government, Australia. Available from: www.health.gov.au/internet/wcms/publishing.nsf/Content/pbac-psd-insulin [Last accessed 4 May, 2006]

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.